Boston Therapeutics (BTHE) 0.4000 $BTHE
Boston Therapeutics' Hong Kong Affiliate Receives Department of Health Certificate to Initiate SUGARDOWN(R) Clinical Trial
Marketwired - Tue Jan 27, 6:34AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), received a signed certificate from the Department of Health to initiate a clinical trial at The Chinese University of Hong Kong (CUHK) evaluating SUGARDOWN(R) in subjects with pre-diabetes. The clinical trial is expected to start this quarter.
Boston Therapeutics' sugardown(R) Significantly Reduces Glucose, Fructose and Insulin Levels in Sugary Soft Drinks
Marketwired - Tue Jan 20, 6:01AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) released additional trial results from its Sydney University study that showed consumption of sugardown(R) tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose and insulin responses to the sugary soft drink beverage. Every subject had a reduction response. Specifically, two sugardown(R) tablets were found to reduce glucose and fructose levels by up to a total of 20 percent and insulin levels by up to 14 percent. Four sugardown(R) tablets were found to reduce total glucose and fructose levels by up to 28 percent and insulin levels by up to18 percent. These new data, which includes fructose levels, are in addition to the topline study results that were announced earlier this month that there was an average reduction in glycemic index (GI) of approximately 10 percent following soft drink consumption with two sugardown(R) tablets.
Boston Therapeutics to Present at 8th Annual OneMedForum Conference in San Francisco
Marketwired - Wed Jan 07, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will be a presenting company at the 8th Annual OneMedForum Conference to be held at the San Francisco Marriott Marquis in San Francisco, CA.
Boston Therapeutics' sugardown(R) Shown to Reduce Glucose Levels Following Consumption of Sugary Beverages
Marketwired - Tue Jan 06, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, announced that a study at Sydney University's Glycemic Index Research Service (SUGiRS) demonstrated an average reduction in glycemic index (GI) of approximately 10 percent following soft drink consumption with sugardown(R). The now-completed trial, which was co-sponsored by Boston Therapeutics and SugarDown Co Ltd (Hong Kong), was the first to evaluate sugardown(R)'s effectiveness with sugary beverages. The primary outcomes of the study were postprandial incremental glucose area under the curve (iAUC) and postprandial incremental insulin area under the curve (iAUC).
Boston Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of BTI-320 to Treat Type ll Diabetes and Weight Loss
Marketwired - Wed Dec 10, 7:21AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced that the U.S. Food and Drug Administration ("FDA"
has accepted the company's Investigational New Drug Application ("IND" for BTI-320 to treat Type 2 diabetes and weight management. The primary endpoints for the multicenter trial are the mean change in Hemoglobin A1c (or HbA1c) and weight loss. The Joslin Diabetes Center in Boston will be the lead clinic in the trial, which is planned to begin in the first quarter of 2015.
Boston Therapeutics and Advance Pharmaceutical Expand Agreement to Market sugardown(R) in 12 Additional Countries in Asia
Marketwired - Fri Nov 21, 6:41AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and Advance Pharmaceutical Company Ltd., via its subsidiary Sugardown Company Ltd. of Hong Kong, have agreed to expand their marketing agreement for Boston Therapeutics' sugardown(R) to include 12 additional countries in Asia. The territory expansion comes as a result of the continued regulatory filings and marketing clearance authorizations that are being granted as Advance continues its market registration expansion.
Boston Therapeutics Initiates Clinical Study at Sydney University to Evaluate sugardown(R) With Sugary Beverage Consumption
Marketwired - Wed Nov 19, 2:43PM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and SugarDown Co Ltd (Hong Kong), are jointly sponsoring a study, which was initiated this week at Sydney University's Glycemic Index Research Service (SUGiRS), to determine postprandial glucose and insulin response to soft drink consumption with sugardown(R). This is the first study to evaluate sugardown(R)'s effectiveness with sugary beverages.
Boston Therapeutics EPS of -$0.03
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:20PM CST
Boston Therapeutics Reports Third Quarter Results and Provides Corporate Update
Marketwired - Fri Nov 07, 10:56AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, today reported its financial results for the third quarter and nine months ended September 30, 2014 and provided a corporate update.
Boston Therapeutics Announces the North America Branding of sugardown(R): A New Natural Product That Helps Maintain Healthy Blood Sugar Levels
Marketwired - Mon Nov 03, 7:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a developer of complex carbohydrate therapeutics to manage post meal blood glucose levels, announced that Benchworks SD, LLC launched the branding of sugardown(R) in North America. sugardown(R) is a new natural dietary supplement product that helps people maintain healthy blood sugar levels. sugardown(R) is the first chewable tablet of its kind. It was designed for people who are committed to a balanced diet and exercise to help keep their blood sugar levels healthy.
Boston Therapeutics Reports Topline U.S.-Based Phase IIb Study Results of BTI-320 in Patients With Type 2 Diabetes
Marketwired - Thu Oct 09, 7:39AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a developer of complex carbohydrate therapeutics to manage post meal blood glucose levels and inflammatory diseases, reports results from its Phase IIb clinical study of BTI-320 in patients with type 2 diabetes (SD-002) conducted in the U.S. by Accumed Research Associates in Garden City, NY.
Boston Therapeutics Appoints David S.H. Bell, MB, FACP, FACE to Its Medical Advisory Board
Marketwired - Wed Oct 08, 6:01AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a developer of complex carbohydrate therapeutics designed to treat pre-diabetes, diabetes and inflammatory diseases, has appointed David S.H. Bell, MB, FACP, FACE, to its Medical Advisory Board. This increases the number of members of the Board to eight.
Boston Therapeutics Files Patent Application for Novel Therapeutic Uses of BTI-320
Marketwire - Tue Oct 07, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a developer of complex carbohydrate therapeutics to treat pre-diabetes, diabetes and inflammatory diseases, has filed a patent application directed to novel therapeutic uses of its lead product candidate, BTI-320.
Boston Therapeutics Appoints Jan Brinkman, M.D., Ph.D. and Alan M. Hoberman, Ph.D. to Board of Directors
Marketwire - Wed Oct 01, 12:47PM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Jan Brinkman, M.D., Ph.D. and Alan M. Hoberman, Ph.D. to its Board of Directors, effective immediately. This increases the total number of Board members to eight.
MRK: 58.81 (-0.07)
Benchworks Collaborates With Boston Therapeutics to Market sugardown(R)
Marketwire - Mon Sep 29, 6:00AM CDT
Benchworks is pleased to announce the launch of the commercial phase of sugardown(R), a dietary supplement developed by Boston Therapeutics, Inc. (OTCQB: BTHE), that is clinically proven to help control glucose levels when combined with diet and exercise. It is a non-systemic, chewable, complex carbohydrate-based compound, specifically designed to help maintain healthy glucose levels throughout the day. Intended to be taken before meals, sugardown(R) works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars. This process reduces the amount of glucose available to be absorbed into the bloodstream.
Boston Therapeutics hires Dr. Meng Hee Tan as consulting medical director
M2 - Wed Sep 24, 5:51AM CDT
Carbohydrate therapeutics company Boston Therapeutics (OTCQB:BTHE) revealed on Tuesday the election of DR. Meng Hee Tan, M.D. as its consulting medical director.
Boston Therapeutics Appoints Meng Hee Tan, M.D. to Consulting Medical Director
Marketwire - Tue Sep 23, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Meng Hee Tan, M.D. to serve as its Consulting Medical Director.
Boston Therapeutics Signs Clinical Trial Agreement With Prestigious Joslin Diabetes Center for Phase III Study of BTI-320
Marketwire - Mon Sep 22, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a developer of complex carbohydrate therapeutics to treat diabetes, has signed a clinical trial agreement with the prestigious Joslin Diabetes Center in Boston to be a site for a Phase III study of BTI-320, a new generation of alpha glucosidase inhibitors designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes.
Boston Therapeutics to Present Findings of BTI-320 as Therapy for Glycemic Control at 50th Annual Meeting of European Association for the Study of Diabetes
Marketwire - Tue Sep 16, 6:21AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will present data on BTI-320, its lead drug candidate, as a poster presentation at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD 2014), to be held September 15-19 in Vienna, Austria.
Boston Therapeutics' Hong Kong Affiliate Receives Department of Health Certificate to Initiate SUGARDOWN(R) Clinical Trial
Marketwired - Tue Jan 27, 6:34AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), received a signed certificate from the Department of Health to initiate a clinical trial at The Chinese University of Hong Kong (CUHK) evaluating SUGARDOWN(R) in subjects with pre-diabetes. The clinical trial is expected to start this quarter.
Boston Therapeutics' sugardown(R) Significantly Reduces Glucose, Fructose and Insulin Levels in Sugary Soft Drinks
Marketwired - Tue Jan 20, 6:01AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) released additional trial results from its Sydney University study that showed consumption of sugardown(R) tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose and insulin responses to the sugary soft drink beverage. Every subject had a reduction response. Specifically, two sugardown(R) tablets were found to reduce glucose and fructose levels by up to a total of 20 percent and insulin levels by up to 14 percent. Four sugardown(R) tablets were found to reduce total glucose and fructose levels by up to 28 percent and insulin levels by up to18 percent. These new data, which includes fructose levels, are in addition to the topline study results that were announced earlier this month that there was an average reduction in glycemic index (GI) of approximately 10 percent following soft drink consumption with two sugardown(R) tablets.
Boston Therapeutics to Present at 8th Annual OneMedForum Conference in San Francisco
Marketwired - Wed Jan 07, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will be a presenting company at the 8th Annual OneMedForum Conference to be held at the San Francisco Marriott Marquis in San Francisco, CA.
Boston Therapeutics' sugardown(R) Shown to Reduce Glucose Levels Following Consumption of Sugary Beverages
Marketwired - Tue Jan 06, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, announced that a study at Sydney University's Glycemic Index Research Service (SUGiRS) demonstrated an average reduction in glycemic index (GI) of approximately 10 percent following soft drink consumption with sugardown(R). The now-completed trial, which was co-sponsored by Boston Therapeutics and SugarDown Co Ltd (Hong Kong), was the first to evaluate sugardown(R)'s effectiveness with sugary beverages. The primary outcomes of the study were postprandial incremental glucose area under the curve (iAUC) and postprandial incremental insulin area under the curve (iAUC).
Boston Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of BTI-320 to Treat Type ll Diabetes and Weight Loss
Marketwired - Wed Dec 10, 7:21AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced that the U.S. Food and Drug Administration ("FDA"
has accepted the company's Investigational New Drug Application ("IND" for BTI-320 to treat Type 2 diabetes and weight management. The primary endpoints for the multicenter trial are the mean change in Hemoglobin A1c (or HbA1c) and weight loss. The Joslin Diabetes Center in Boston will be the lead clinic in the trial, which is planned to begin in the first quarter of 2015. Boston Therapeutics and Advance Pharmaceutical Expand Agreement to Market sugardown(R) in 12 Additional Countries in Asia
Marketwired - Fri Nov 21, 6:41AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and Advance Pharmaceutical Company Ltd., via its subsidiary Sugardown Company Ltd. of Hong Kong, have agreed to expand their marketing agreement for Boston Therapeutics' sugardown(R) to include 12 additional countries in Asia. The territory expansion comes as a result of the continued regulatory filings and marketing clearance authorizations that are being granted as Advance continues its market registration expansion.
Boston Therapeutics Initiates Clinical Study at Sydney University to Evaluate sugardown(R) With Sugary Beverage Consumption
Marketwired - Wed Nov 19, 2:43PM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and SugarDown Co Ltd (Hong Kong), are jointly sponsoring a study, which was initiated this week at Sydney University's Glycemic Index Research Service (SUGiRS), to determine postprandial glucose and insulin response to soft drink consumption with sugardown(R). This is the first study to evaluate sugardown(R)'s effectiveness with sugary beverages. Boston Therapeutics EPS of -$0.03
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:20PM CST
Boston Therapeutics Reports Third Quarter Results and Provides Corporate Update
Marketwired - Fri Nov 07, 10:56AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, today reported its financial results for the third quarter and nine months ended September 30, 2014 and provided a corporate update.
Boston Therapeutics Announces the North America Branding of sugardown(R): A New Natural Product That Helps Maintain Healthy Blood Sugar Levels
Marketwired - Mon Nov 03, 7:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to manage post meal blood glucose levels, announced that Benchworks SD, LLC launched the branding of sugardown(R) in North America. sugardown(R) is a new natural dietary supplement product that helps people maintain healthy blood sugar levels. sugardown(R) is the first chewable tablet of its kind. It was designed for people who are committed to a balanced diet and exercise to help keep their blood sugar levels healthy. Boston Therapeutics Reports Topline U.S.-Based Phase IIb Study Results of BTI-320 in Patients With Type 2 Diabetes
Marketwired - Thu Oct 09, 7:39AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to manage post meal blood glucose levels and inflammatory diseases, reports results from its Phase IIb clinical study of BTI-320 in patients with type 2 diabetes (SD-002) conducted in the U.S. by Accumed Research Associates in Garden City, NY. Boston Therapeutics Appoints David S.H. Bell, MB, FACP, FACE to Its Medical Advisory Board
Marketwired - Wed Oct 08, 6:01AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics designed to treat pre-diabetes, diabetes and inflammatory diseases, has appointed David S.H. Bell, MB, FACP, FACE, to its Medical Advisory Board. This increases the number of members of the Board to eight. Boston Therapeutics Files Patent Application for Novel Therapeutic Uses of BTI-320
Marketwire - Tue Oct 07, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to treat pre-diabetes, diabetes and inflammatory diseases, has filed a patent application directed to novel therapeutic uses of its lead product candidate, BTI-320. Boston Therapeutics Appoints Jan Brinkman, M.D., Ph.D. and Alan M. Hoberman, Ph.D. to Board of Directors
Marketwire - Wed Oct 01, 12:47PM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Jan Brinkman, M.D., Ph.D. and Alan M. Hoberman, Ph.D. to its Board of Directors, effective immediately. This increases the total number of Board members to eight. MRK: 58.81 (-0.07)
Benchworks Collaborates With Boston Therapeutics to Market sugardown(R)
Marketwire - Mon Sep 29, 6:00AM CDT
Benchworks is pleased to announce the launch of the commercial phase of sugardown(R), a dietary supplement developed by Boston Therapeutics, Inc. (OTCQB: BTHE), that is clinically proven to help control glucose levels when combined with diet and exercise. It is a non-systemic, chewable, complex carbohydrate-based compound, specifically designed to help maintain healthy glucose levels throughout the day. Intended to be taken before meals, sugardown(R) works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars. This process reduces the amount of glucose available to be absorbed into the bloodstream.
Boston Therapeutics hires Dr. Meng Hee Tan as consulting medical director
M2 - Wed Sep 24, 5:51AM CDT
Carbohydrate therapeutics company Boston Therapeutics (OTCQB:BTHE) revealed on Tuesday the election of DR. Meng Hee Tan, M.D. as its consulting medical director.
Boston Therapeutics Appoints Meng Hee Tan, M.D. to Consulting Medical Director
Marketwire - Tue Sep 23, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Meng Hee Tan, M.D. to serve as its Consulting Medical Director. Boston Therapeutics Signs Clinical Trial Agreement With Prestigious Joslin Diabetes Center for Phase III Study of BTI-320
Marketwire - Mon Sep 22, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to treat diabetes, has signed a clinical trial agreement with the prestigious Joslin Diabetes Center in Boston to be a site for a Phase III study of BTI-320, a new generation of alpha glucosidase inhibitors designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes. Boston Therapeutics to Present Findings of BTI-320 as Therapy for Glycemic Control at 50th Annual Meeting of European Association for the Study of Diabetes
Marketwire - Tue Sep 16, 6:21AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will present data on BTI-320, its lead drug candidate, as a poster presentation at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD 2014), to be held September 15-19 in Vienna, Austria. 
